#top pharma companies 2013
8. Bayer HealthCare
2013 revenue:€18.924 billion ($25.969 billion)
2012 revenue: €18.604 billion ($24.300 billion)
Bayer’s sitting pretty as far as its pharma lineup goes. The German company counts blood thinner Xarelto and eye med Eylea among its revenue-makers, and those make up a pretty big one-two combo. Together, the pair helped Bayer’s pharma sales balloon 9.4% in 2013, reaching €11.2 billion; along with cancer therapies Stivarga and Xofigo and pulmonary hypertension treatment Adempas, they posted a combined €1.5 billion in 2013 sales.
Bayer expects big things from those drugs going forward, too: The company recently raised their sales forecast, and it now projects the pack of new sellers will together turn in peak sales of €7.5 billion ($10.3 billion) or more. But that’s not to say the company won’t get growth from standbys; clotting med and blockbuster orphan drug Kogenate, for one, put up a 6.4% sales hike in 2013.
As CEO Marijn Dekkers noted when announcing the year’s financial results, Bayer’s consumer care unit also saw “positive sales development,” growing by 3.2% to hit €7.7 billion. The company has been pursuing an expansion strategy focusing on bolt-on acquisitions, most recently nabbing Chinese OTC maker Dihon Pharmaceutical Group. That pickup should put Bayer in a leading position in China’s OTC industry, the company said.
And there could be even bigger deals on the way. Bayer is reportedly among the companies eyeing Merck’s ($MRK) consumer health unit, which could draw bids of up to $12 billion. Dekkers said late last year that the company is also committed to expanding its animal health division, and some speculated last December that it may be interested in Novartis’ ($NVS) unit, which is rumored to be up for grabs as the result of a company-wide review.
Special Reports: Top Pharma Companies by 2012 Revenues – Bayer HealthCare | Top 15 Drug Launch Superstars – Eylea – Xarelto
Once again, Bayer’s new drugs power pharma sales upward
Bayer’s new drugs shine, fueling 5.5% pharma growth